Hormone Replacement Therapy Side Effects: Common Risks and Warnings

Why Hormone Replacement Therapy Causes Side Effects

Hormone replacement therapy supplements declining estrogen, progesterone, or both during perimenopause and menopause. Introducing exogenous hormones alters the body's established feedback loops, affecting tissues with hormone receptors throughout the cardiovascular system, breasts, uterus, brain, bones, and skin. Side effects arise because these tissues respond to hormone levels that may exceed, fall short of, or fluctuate differently than the body's own production.

The type, dose, route of administration, and treatment duration all influence which side effects appear and how intensely. Oral estrogen passes through the liver first, increasing clotting factors and triglycerides more than transdermal patches, gels, or sprays that bypass first-pass metabolism. Progestogens vary in their androgenic, glucocorticoid, and mineralocorticoid activity, shaping side effect profiles. Individual factors — age at initiation, time since menopause, genetics, body mass index, and pre-existing conditions — further modify risk.

Common Short-Term Side Effects

Most women starting HRT experience transient symptoms as the body adjusts to new hormone levels. Breast tenderness, bloating, headaches, nausea, and mood swings frequently occur within the first three months. Irregular vaginal bleeding or spotting affects up to 40 percent of women on combined continuous regimens during the first six months. These effects often diminish as hormone levels stabilize and the endometrium adapts.

Fluid retention can cause weight fluctuations of one to three kilograms. Skin changes — increased oiliness, acne, or melasma — may appear, particularly with androgenic progestogens. Some women report increased vaginal discharge or yeast infections. Sleep disturbances, including vivid dreams or insomnia, occasionally accompany progesterone or progestin use, especially at higher doses or with oral formulations taken at bedtime.

• Breast tenderness or swelling
• Bloating and fluid retention
• Headaches or migraine exacerbation
• Nausea, often reduced by taking with food
• Mood changes including irritability or low mood
• Unscheduled vaginal bleeding or spotting
• Skin changes: acne, oiliness, melasma
• Sleep disturbances with oral progesterone

Serious Long-Term Risks and Health Warnings

The Women's Health Initiative and subsequent studies identified several serious risks that vary by formulation, timing, and patient profile. Combined estrogen-progestogen therapy increases breast cancer risk after three to five years of use, with risk rising with duration and declining after cessation. Estrogen-only therapy in women with a uterus markedly increases endometrial cancer risk; adding a progestogen eliminates this excess risk but introduces the breast cancer concern.

Venous thromboembolism risk doubles to triples with oral estrogen, particularly in the first year. Transdermal estrogen at standard doses does not appear to increase VTE risk significantly. Stroke risk rises with oral estrogen, especially in women over 60 or more than 10 years postmenopause. Coronary heart disease risk shows a timing hypothesis: initiation before age 60 or within 10 years of menopause may be neutral or protective, while later initiation increases risk. Gallbladder disease incidence rises 50 to 100 percent with oral estrogen.

Factors That Modify Individual Risk

Age at initiation is the single strongest modifier. Women starting HRT before age 60 or within 10 years of menopause onset generally have more favorable benefit-risk ratios for cardiovascular outcomes and mortality than those starting later. Obesity amplifies VTE risk with oral estrogen but may reduce fracture benefit. Smoking compounds cardiovascular risks and reduces estrogen efficacy. Personal or family history of breast cancer, VTE, stroke, or liver disease shifts the calculus toward non-hormonal alternatives or transdermal routes.

Genetic polymorphisms affect hormone metabolism and receptor sensitivity. Factor V Leiden or prothrombin gene mutations dramatically increase VTE risk with oral estrogen. CYP enzyme variants alter estrogen and progestogen clearance, influencing both efficacy and side effect intensity. Breast density, prior benign breast disease, and reproductive history (age at menarche, parity, breastfeeding) modulate breast cancer risk. These factors underscore why guidelines emphasize individualized assessment rather than universal prescribing.

• Age at initiation and years since menopause
• Body mass index and metabolic health
• Smoking status
• Personal or family history of breast cancer
• History of venous thromboembolism or clotting disorders
• Cardiovascular disease risk factors
• Liver disease or gallbladder history
• Genetic factors (Factor V Leiden, CYP variants)

Monitoring, Management, and When to Seek Care

Routine follow-up at three months, then annually, allows dose adjustment and side effect management. Blood pressure, weight, and breast examination should be documented. Mammography screening follows age-appropriate guidelines regardless of HRT use, though denser breasts may require supplemental imaging. Transvaginal ultrasound is not routinely recommended for endometrial surveillance in women on appropriate combined regimens unless bleeding persists beyond six months.

Dose reduction often resolves breast tenderness, bloating, and headaches. Switching from oral to transdermal estrogen mitigates VTE and triglyceride concerns. Changing progestogen type — for example, from medroxyprogesterone acetate to micronized progesterone — can improve mood, sleep, and metabolic profiles. For persistent unscheduled bleeding, options include increasing progestogen dose, switching to a sequential regimen, or evaluating for endometrial pathology. Women should contact their clinician promptly for sudden severe headache, vision changes, leg swelling or pain, shortness of breath, chest pain, or a new breast lump — signs of stroke, pulmonary embolism, or other urgent complications.

• Sudden severe headache or migraine with aura
• Vision changes or speech difficulty
• Unilateral leg swelling, warmth, or pain
• Shortness of breath or chest pain
• New breast lump or persistent breast change
• Heavy or prolonged vaginal bleeding after 6 months
• Severe abdominal pain
• Jaundice or dark urine